Related Experiment Videos
CYP17 polymorphism and hot flushes in postmenopausal women
A M Massad-Costa1, N C Nogueira-de-Souza, C V de Carvalho
1Federal University of Sao Paulo, Sao Paulo.
Climacteric : the Journal of the International Menopause Society
|September 11, 2008
Summary
This study found no significant link between the CYP17 gene variant and hot flush severity in postmenopausal women. Further research is needed to understand genetic influences on vasomotor symptoms.
Area of Science:
- Genetics
- Menopause Research
- Molecular Biology
Background:
- Hot flushes are common vasomotor symptoms experienced by postmenopausal women.
- Genetic factors may influence the susceptibility and severity of hot flushes.
- The CYP17 gene is involved in steroid hormone synthesis, potentially impacting menopausal symptoms.
Purpose of the Study:
- To examine the association between CYP17alpha gene polymorphism and the occurrence and severity of hot flushes in postmenopausal women.
- To determine if specific CYP17 genotypes or alleles correlate with increased risk or intensity of hot flushes.
Main Methods:
- A cohort of 93 non-hysterectomized, postmenopausal women was recruited.
- Vasomotor symptoms, including hot flushes, were assessed at baseline.
- CYP17alpha gene polymorphism was analyzed using PCR-RFLP on genomic DNA from peripheral blood lymphocytes.
Main Results:
- No statistically significant difference was observed in the severity of hot flushes across different CYP17 genotypes or allele frequencies.
- The odds ratio for hot flush severity associated with the CYP17 allele was 1.17 (p = 0.61), indicating no significant association.
- The CYP17 MspAI polymorphism did not demonstrate a significant link to an increased risk of reporting hot flushes.
Conclusions:
- The CYP17 MspAI polymorphism is not significantly associated with hot flushes in the studied postmenopausal population.
- Genetic variations in CYP17 may not be a primary determinant of hot flush experience.
- Further investigation into other genetic and environmental factors influencing hot flushes is warranted.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...